FGFBP2 (Fibroblast Growth Factor Binding Protein 2), a secreted chaperone, regulates fibroblast growth factors (FGFs)—key signaling molecules critical for tissue repair, angiogenesis, and cell proliferation—by binding specific ligands (e.g., FGF-1, FGF-2) through a conserved domain to enhance their release from extracellular storage or receptor interactions. Primarily expressed in regenerative or metabolically active tissues (e.g., liver, kidney, epithelia), FGFBP2 is tightly controlled under normal conditions but often overexpressed in cancers, where it amplifies FGF-driven tumor progression by promoting angiogenesis, survival, and metastasis, while also being implicated in metabolic disorders and inflammation through potential links to insulin resistance and fibrosis. Though functionally overlapping with its paralog FGFBP1, FGFBP2 exhibits distinct tissue-specific expression and ligand preferences, with ongoing research focused on elucidating its mechanistic roles in FGF signaling and exploring its therapeutic or biomarker potential in cancer and FGF-associated diseases.
FGFR1; also known as CD331; belongs to the fibroblast growth factor receptor subfamily where amino acid sequence is highly conserved between members and throughout evolution. FGFR family members differ from one another in their ligand affinities and tissue distribution. Fibroblast growth factors (FGFs) (FGF1 - 10 and 16 - 23) are mitogenic signaling molecules that have roles in angiogenesis; wound healing; cell migration; neural outgrowth and embryonic development. FGFs bind heparan sulfate glycosaminoglycans; which facilitates dimerization (activation) of FGF receptors. FGFR1 is a full-length representative protein consists of an extracellular region; composed of three immunoglobulin-like domains; a single hydrophobic membrane-spanning segment and a cytoplasmic tyrosine kinase domain. The extracellular portion of FGFR1 interacts with fibroblast growth factors; setting in motion a cascade of downstream signals; ultimately influencing mitogenesis and differentiation. This particular family member binds both acidic and basic fibroblast growth factors and is involved in limb induction. CD331 can be detected in astrocytoma; neuroblastoma and adrenal cortex cell lines. Some isoforms are detected in foreskin fibroblast cell lines; however isoform 17; isoform 18 and isoform 19 are not detected in these cells. Defects in FGFR1 are a cause of Pfeiffer syndrome ;idiopathic hypogonadotropic hypogonadism; Kallmann syndrome type 2; osteoglophonic dysplasia and trigonocephaly non-syndromic.
FGF R5 is a widely expressed type I transmembrane protein belonging to the FGF receptor family. It shares approximately 32% amino acid sequence identity to the extracellular domains of FGF R1-4, but does not contain a cytoplasmic tyrosine kinase domain.
FGFR2, also known as CD332, belongs to the fibroblast growth factor receptor subfamily where amino acid sequence is highly conserved between members and throughout evolution. FGFR2 acts as cell-surface receptor for fibroblast growth factors and plays an essential role in the regulation of cell proliferation, differentiation, migration and apoptosis, and in the regulation of embryonic development. It is required for normal embryonic patterning, trophoblast function, limb bud development, lung morphogenesis, osteogenesis and skin development. FGFR2 plays an essential role in the regulation of osteoblast differentiation, proliferation and apoptosis, and is required for normal skeleton development. It also promotes cell proliferation in keratinocytes and imature osteoblasts, but promotes apoptosis in differentiated osteoblasts. FGFR2 signaling is down-regulated by ubiquitination, internalization and degradation. Mutations that lead to constitutive kinase activation or impair normal CD332 maturation, internalization and degradation lead to aberrant signaling. Over-expressed FGFR2 promotes activation of STAT1. Defects in CD3322 are the cause of Crouzon syndrome, Jackson-Weiss syndrome, Apert syndrome, Pfeiffer syndrome, Beare-Stevenson cutis gyrata syndrome, familial scaphocephaly syndrome, lacrimo-auriculo-dento-digital syndrome and Antley-Bixler syndrome without genital anomalies or disordered steroidogenesis.
FGFR3, also known as CD333, is a member of the fibroblast growth factor receptor (FGFR) family, with its amino acid sequence being highly conserved between members and among divergent species. FGFR family members differ from one another in their ligand affinities and tissue distribution. FGFRs are transmembrane catalytic receptors that have intracellular tyrosine kinase activity. Mutations in FGFR genes are the cause of several human developmental disorders characterized by skeletal abnormalities such as achondroplasia, and upregulation of FGFR expression may lead to cell transformation and cancer. FGFR3, a full-length representative protein would consist of an extracellular region, composed of three immunoglobulin-like domains, a single hydrophobic membrane-spanning segment and a cytoplasmic tyrosine kinase domain. The extracellular portion of FGFR3 interacts with fibroblast growth factors, setting in motion a cascade of downstream signals, ultimately influencing mitogenesis and differentiation. FGFR3 binds acidic and basic fibroblast growth hormone and plays a role in bone development and maintenance. Mutations in FGFR3 gene lead to craniosynostosis and multiple types of skeletal dysplasia. Three alternatively spliced transcript variants that encode different protein isoforms have been described. CD333 is the receptor for acidic and basic fibroblast growth factors.
Lascia la tua email e seleziona le aree che vuoi seguire per ricevere novita di prodotto, approfondimenti tecnici e promozioni piu pertinenti.
Puoi scegliere le macro-aree Life Science e Diagnostica oppure le singole specializzazioni.
Seleziona uno o piu ambiti di interesse per ricevere comunicazioni piu utili e mirate.
Aggiornamenti su ricerca, strumentazione e applicazioni per il mondo Life Science.
Novita, approfondimenti e promozioni per laboratori diagnostici e flussi operativi.
2025 TEMA Ricerca - All Rights Reserved.
